X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the agreement, Collegium will exclusively manufacture and supply Hikma with all authorized generic products for sale, including Nucynta-Generic (tapentadol HCl).
Lead Product(s): Tapentadol
Therapeutic Area: Neurology Product Name: Nucynta-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hikma Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 29, 2024
Details:
ELYXYB™ (celecoxib) oral solution is prescription nonsteroidal anti-inflammatory drug (NSAID) used for the acute treatment of migraine with or without aura in adult.
Lead Product(s): Celecoxib
Therapeutic Area: Neurology Product Name: Elyxyb
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Details:
Diversifies and expands Collegium’s revenues by adding BELBUCA® as a second and highly complementary growth driver to Collegium’s highly differentiated pain portfolio, in addition to a contributor with SYMPROIC®, and a new product launch opportunity with ELYXYB.
Lead Product(s): Buprenorphine
Therapeutic Area: Neurology Product Name: Belbuca
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: BioDelivery Sciences
Deal Size: $604.0 million Upfront Cash: $604.0 million
Deal Type: Acquisition March 22, 2022
Details:
Diversifies and expands Collegium’s revenues by adding BELBUCA as a second and highly complementary growth driver to Collegium’s highly differentiated pain portfolio, in addition to a contributor with Symproic, and a new product launch opportunity with ELYXYB.
Lead Product(s): Buprenorphine
Therapeutic Area: Neurology Product Name: Belbuca
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: BioDelivery Sciences
Deal Size: $604.0 million Upfront Cash: $604.0 million
Deal Type: Acquisition February 14, 2022
Details:
BELBUCA® (buprenorphine) is a medication administered to help manage chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Lead Product(s): Buprenorphine
Therapeutic Area: Neurology Product Name: Belbuca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alvogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2021
Details:
BDSI intends to launch ELYXYB in the first quarter of 2022. Additionally, BDSI plans to conduct an ELYXYB pediatric study, which will have the potential to address the significant unmet needs of pediatric and adolescent patients suffering from migraine attacks.
Lead Product(s): Celecoxib
Therapeutic Area: Neurology Product Name: Elyxyb
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Dr. Reddy\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 09, 2021
Details:
ELYXYB is an oral solution of celecoxib, formulated using a self-micro emulsifying drug delivery system that improves solubility and bioavailability of the drug leading to better absorption.
Lead Product(s): Celecoxib
Therapeutic Area: Neurology Product Name: Elyxyb
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Dr. Reddy\'s Laboratories
Deal Size: $15.0 million Upfront Cash: $6.0 million
Deal Type: Acquisition August 04, 2021
Details:
Data from a placebo-controlled study compared safety outcomes of BELBUCA® versus oral oxycodone. BELBUCA® is a buprenorphine buccal film is indicated for the management of severe pain.
Lead Product(s): Buprenorphine
Therapeutic Area: Neurology Product Name: Belbuca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2021
Details:
BELBUCA effect on respiratory drive was comparable to placebo at all doses tested.The effect of immediate release oral oxycodone HCl resulted in a dose-dependent decrease in respiratory drive.
Lead Product(s): Buprenorphine
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
